Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...

Bristol Myers Squibb presents data across targeted protein degradation research including CELMoD agents and BCL6 ligand-directed degrader at EHA 2025: Princeton, New Jersey Friday ...

ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association ...

Heme oxygenase catalyzes the first step in the oxidative degradation of heme. The crystal structure of heme oxygenase-1 (HO-1) reported here reveals a novel helical fold with the heme sandwiched ...

Department of Chemistry, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, and Advanced Materials Laboratory, Sandia National Laboratories, 1001 University Boulevard SE, ...

June 05, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced ...

Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models ...

Please provide your email address to receive an email when new articles are posted on . The addition of anlotinib to standard of care for newly diagnosed glioblastoma significantly improved PFS in ...

PRESTO, Japan Science and Technology Agency (JST), Department of Chemistry and Biochemistry, Graduate School of Engineering, Kyushu University, Fukuoka 812-8581, Japan, Research Center for Materials ...

today announced it will share 23 abstracts featuring new data across its hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, ...